Patient-derived tumor antigens presented via MHC class I and II on autologous dendritic cells (DC-presented tumor antigens)

Patient-derived tumor antigens presented via MHC class I and II on autologous dendritic cells represent a personalized immunotherapy strategy designed to elicit a specific and robust anti-tumor immune response. This approach involves the isolation of a patient's own dendritic cells (DCs), which are then loaded ex vivo with tumor-specific antigens—ranging from neoantigens identified via genomic sequencing to whole tumor lysates (Liau et al., 2023). These loaded DCs process the antigens and present them on their surface via Major Histocompatibility Complex (MHC) Class I and Class II molecules. Upon re-infusion, these professional antigen-presenting cells migrate to the lymph nodes, where they activate CD8+ cytotoxic T cells and CD4+ helper T cells, respectively (Sabado et al., 2017). This dual activation is critical for overcoming the immunosuppressive tumor microenvironment and establishing long-term immunological memory against the cancer. Clinical applications of this target include the treatment of glioblastoma, melanoma, and prostate cancer, with drugs like Sipuleucel-T and DCVax-L demonstrating the therapeutic potential of this platform (Kantoff et al., 2010).

Other names

Autologous dendritic cell vaccinePersonalized tumor neoantigensDC-based immunotherapyMHC-restricted tumor antigensAutologous DC-Ag complex

The mechanism involves the ex vivo sensitization of autologous dendritic cells with patient-derived tumor antigens, which are then processed and displayed on the cell surface via MHC Class I and II molecules. Upon re-administration, these professional antigen-presenting cells migrate to the lymph nodes to activate naive T cells, specifically priming CD8+ cytotoxic T lymphocytes and CD4+ helper T cells to recognize and eliminate tumor cells expressing those specific antigens (Sabado et al., 2017; PMID: 30108610).